Cargando…

Ex Vivo Immune Responsiveness to SARS-CoV-2 Omicron BA.5.1 Following Vaccination with Unmodified mRNA-Vaccine

(1) Background: The high incidence of SARS-CoV-2 infection in vaccinated persons underscores the importance of individualized re-vaccination. PanIg antibodies that act against the S1/-receptor binding domain quantified in serum by a routine diagnostic test (ECLIA, Roche) can be used to gauge the ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuechler, Anna Sabrina, Heger, Eva, Wirtz, Maike, Weinhold, Sandra, Uhrberg, Markus, Boege, Fritz, Schulze-Bosse, Karin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055845/ https://www.ncbi.nlm.nih.gov/pubmed/36992182 http://dx.doi.org/10.3390/vaccines11030598

Ejemplares similares

A Diagnostic Strategy for Gauging Individual Humoral Ex Vivo Immune Responsiveness Following COVID-19 Vaccination
por: Kuechler, Anna Sabrina, et al.
Publicado: (2022)

Chronic Fatigue and Dysautonomia following COVID-19 Vaccination Is Distinguished from Normal Vaccination Response by Altered Blood Markers
por: Semmler, Amelie, et al.
Publicado: (2023)

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
por: Lutz, Johannes, et al.
Publicado: (2017)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 and BA.5
por: Andreano, Emanuele, et al.
Publicado: (2023)

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Estimation of mRNA COVID-19 Vaccination Effectiveness in Tokyo for Omicron Variants BA.2 and BA.5: Effect of Social Behavior
por: Kodera, Sachiko, et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Riding the Omicron BA.5 Wave: Improved Humoral Response after Vaccination with Bivalent Omicron BA.4-5-Adapted mRNA SARS-CoV-2 Vaccine in Chronic Hemodialysis Patients
por: Ovcar, Eugen, et al.
Publicado: (2023)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods
por: Link-Gelles, Ruth, et al.
Publicado: (2023)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination
por: Bellusci, Lorenza, et al.
Publicado: (2022)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Serum Neutralization of Omicron BA.5, BA.2 and BA.1 in Triple Vaccinated Kidney Transplant Recipients
por: Pedersen, Rune M., et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
por: Shen, Xiaoying, et al.
Publicado: (2022)

Neutralizing response against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients
por: Affeldt, Patrick, et al.
Publicado: (2023)

Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5
por: Diem, Gabriel, et al.
Publicado: (2023)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
por: Li, Gen, et al.
Publicado: (2022)

Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines
por: Bowen, John E., et al.
Publicado: (2022)

Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
por: Kopel, Hagit, et al.
Publicado: (2023)

Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study
por: Mimura, Wataru, et al.
Publicado: (2022)

Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort
por: Itamochi, Masae, et al.
Publicado: (2023)

The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
por: Tuekprakhon, Aekkachai, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2
por: Swart, Maarten, et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
por: Møller Kirsebom, Freja Cordelia, et al.
Publicado: (2022)

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England
por: Kirsebom, Freja C M, et al.
Publicado: (2022)

Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
por: Yao, Lin, et al.
Publicado: (2022)

Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai
por: Wu, Qianhui, et al.
Publicado: (2023)

Immunogenicity of Bivalent Omicron BA.4/5–Adapted Vaccine in Hemodialysis Patients
por: Anft, Moritz, et al.
Publicado: (2023)

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
por: Andreano, Emanuele, et al.
Publicado: (2022)

Delta or Omicron BA.1/2‐neutralizing antibody levels and T‐cell reactivity after triple‐vaccination or infection
por: Rose, Ruben, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ehsaa6lf762ugvra9vafviafh4